

A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

NCT04006808

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	GlaxoSmithKline
Enrollment	184 participants

Key Eligibility Criteria

Inclusion (15)

- Subjects' parent(s)/Legally Acceptable Representative(s) \[LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol
 - Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performance of any study specific procedure.
 - Written informed assent obtained from the subjects when applicable according to local requirements.
 - A male or female between, and including, 1 and 17 years of age at the time of randomisation (Visit Day 1)
 - Body weight e 6 kg/13.23 pounds.
- ... and 10 more (see full listing online)

Exclusion (52)

- Medical conditions
 - Any primary kidney disease with a high incidence of recurrent primary kidney disease within the allograft
 - Evidence of recurrent primary kidney disease within the current allograft
 - Previous allograft loss secondary to recurrent primary kidney disease
 - History of more than one organ transplanted (that is, kidney-liver, simultaneous double kidney or kidney-other organ(s) transplanted).
- ... and 47 more (see full listing online)

Locations (31 total)

GSK Investigational Site, Brussels, Belgium
GSK Investigational Site, Ghent, Belgium
GSK Investigational Site, Leuven, Belgium
... and 28 more locations

<https://clinicaltrials.gov/study/NCT04006808>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).